Savara Inc.

NasdaqGS:SVRA Stock Report

Market Cap: US$646.8m

Savara Management

Management criteria checks 3/4

Savara's CEO is Matt Pauls, appointed in Sep 2020, has a tenure of 4.67 years. total yearly compensation is $4.91M, comprised of 12.6% salary and 87.4% bonuses, including company stock and options. directly owns 0.33% of the company’s shares, worth $2.11M. The average tenure of the management team and the board of directors is 3.1 years and 8.1 years respectively.

Key information

Matt Pauls

Chief executive officer

US$4.9m

Total compensation

CEO salary percentage12.62%
CEO tenure4.7yrs
CEO ownership0.3%
Management average tenure3.1yrs
Board average tenure8.1yrs

Recent management updates

Recent updates

Savara: Make-It-Or-Break-It Molbreevi BLA Filing

Apr 21

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

Apr 03
Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

Savara: Rolling BLA Submission Of MOLBREEVI Generates Catalysts To  Track

Dec 20

Savara: Trial Successful, But I'm Only Half Convinced

Sep 09

Savara: Today's Data 'Win' Rouses Market All Too Briefly

Jun 26

Savara: The Binary Bet On Phase 3 Data

Jun 07

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

Dec 14
Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Feb 16
Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Oct 12
Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Aug 26

Savara GAAP EPS of -$0.06 in-line

Aug 11

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Jan 24
Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Is Savara (NASDAQ:SVRA) A Risky Investment?

Jul 05
Is Savara (NASDAQ:SVRA) A Risky Investment?

CEO Compensation Analysis

How has Matt Pauls's remuneration changed compared to Savara's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$102m

Dec 31 2024US$5mUS$620k

-US$96m

Sep 30 2024n/an/a

-US$83m

Jun 30 2024n/an/a

-US$75m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$4mUS$595k

-US$55m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$43m

Mar 31 2023n/an/a

-US$40m

Dec 31 2022US$2mUS$580k

-US$38m

Sep 30 2022n/an/a

-US$39m

Jun 30 2022n/an/a

-US$39m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$2mUS$560k

-US$43m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$46m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$2mUS$170k

-US$50m

Sep 30 2020n/an/a

-US$68m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$81m

Dec 31 2019US$64kn/a

-US$78m

Sep 30 2019n/an/a

-US$57m

Jun 30 2019n/an/a

-US$57m

Mar 31 2019n/an/a

-US$47m

Dec 31 2018US$114kn/a

-US$62m

Compensation vs Market: Matt's total compensation ($USD4.91M) is about average for companies of similar size in the US market ($USD3.98M).

Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.

CEO

Matt Pauls (53 yo)

4.7yrs
Tenure
US$4,912,011
Compensation

Mr. Matthew Pauls, J.D. M.B.A. also known as Matt, is Director at NVN Liquidation Inc. He serves as Director of Soleno Therapeutics, Inc. since August 15, 2023 and is its Lead Independent Director aince Au...

Leadership Team

NamePositionTenureCompensationOwnership
Matthew Pauls
Chairman & CEO4.7yrsUS$4.91m0.33%
$ 2.1m
David Lowrance
CFO, Chief Administrative Officer & Secretary8.5yrsUS$1.87m0.057%
$ 371.5k
Robert Lutz
Chief Operating Officer2.3yrsUS$1.87m0.048%
$ 312.3k
Kate McCabe
Chief Legal Officer7.2yrsno data0.27%
$ 1.7m
Anne Erickson
Chief Business Officer4.6yrsno data0.083%
$ 536.2k
Brian Maurer
Head of Clinical Operations4yrsno datano data
Charles LaPree
Executive VP & Head of Global Regulatory Affairs3.8yrsno datano data
Raymond Pratt
Chief Medical Officer2.5yrsUS$698.69k0.052%
$ 337.8k
Brian Robinson
Executive Vice President of Global Medical Affairs2.1yrsno datano data
Yasmine Wasfi
Executive VP and Head of Clinical Development & Clinical Operations1.4yrsno datano data
Siddharth Advant
Executive Vice President of Global Technical Operations1.2yrsno datano data
Braden Parker
Chief Commercial Officerless than a yearno datano data
3.1yrs
Average Tenure
53yo
Average Age

Experienced Management: SVRA's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Matthew Pauls
Chairman & CEO8.1yrsUS$4.91m0.33%
$ 2.1m
David Ramsay
Independent Director8.1yrsUS$194.25k1.17%
$ 7.6m
Joseph S. McCracken
Lead Independent Director11.6yrsUS$196.50k0.10%
$ 647.3k
Richard Hawkins
Independent Director14.6yrsUS$183.00k0.013%
$ 83.6k
Nevan Elam
Independent Director16.3yrsUS$191.50k0.011%
$ 69.1k
Bruce Trapnell
Member of Clinical Advisory Boardno datano datano data
Francesco Bonella
Member of Clinical Advisory Boardno datano datano data
Yoshikazu Inoue
Member of Clinical Advisory Boardno datano datano data
An van Es-Johansson
Independent Director5.4yrsUS$189.50k0.011%
$ 69.1k
Cormac McCarthy
Member of Clinical Advisory Board4.3yrsno datano data
8.1yrs
Average Tenure
61.5yo
Average Age

Experienced Board: SVRA's board of directors are considered experienced (8.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 13:08
End of Day Share Price 2025/05/19 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Savara Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dewey SteadmanCanaccord Genuity
Liisa BaykoCitizens JMP Securities, LLC
Jonathan WollebenCitizens JMP Securities, LLC